Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update.
Share Talk Bulletin Board Heroes, Thursday 19th September 2019
Share Talk Bulletin Board Heroes, Monday 22nd July 2019
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update.
Share Talk Bulletin Board Heroes, Monday 15th July 2019
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update. e-Therapeutics plc (ETX) GCM Resources
Share Talk Bulletin Board Heroes, Friday 23rd November 2018
A charting look at some of the most followed stocks on the London market, Zak Mir covers.
Share Talk Bulletin Board Heroes, Monday, 12th November 2018
A charting look at some of the most followed stocks on the London market, Zak Mir covers.
Share Talk Bulletin Board Heroes, Thursday, 8th November 2018
A charting look at some of the most followed stocks on the London market, Zak Mir covers.
N4 Pharma PLC (AIM:N4P) Research collaboration update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments, today provides an update on its collaboration with MedImmune, following the
N4 Pharma PLC (AIM:N4P) Nuvec® research update
Nigel Theobald, CEO of N4 Pharma commented: These results are another positive step forward for our Nuvec® delivery platform.
Share Talk Bulletin Board Heroes: 25th Sep 2018
A charting look at some of the most followed stocks on the London market, Zak Mir covers.
N4 Pharma PLC (AIM:N4P) Filing of Patent
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company which improves the delivery of existing drugs and novel vaccines and therapeutics, is pleased to announce the filing of its
N4 Pharma PLC (AIM:N4P) Nuvec® Update
Nuvec® Update N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, is pleased to provide an update on its Nuvec®
